Project Grant R41AI167161
Award Date
8/12/22
Completion Date
7/31/23
Dollars Obligated
$519K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Ciencia Inc. (Q7TKCXQFD2J1)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
East Hartford, CT 06108, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $971,664 to Biopeptides Corp to develop a point-of-care assay for the detection of Babesia microti and diagnosis of Lyme disease. The project aims to: 1) derive high-affinity monoclonal antibodies to detect Babesia microti secreted antigen, and 2) develop a combined vertical flow assay that can simultaneously...
This Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel protein-based prophylactic drug, FC3/SCR(19-20), to prevent Lyme disease and relapsing fever. The primary awardee, Planet Biotechnology Inc., will use its plant-based expression system to produce and optimize variants of this fusion protein to enhance bioavailability, safety, and...
The National Science Foundation (NSF) awarded a $550,000 Project Grant under the NSF Technology, Innovation, and Partnerships (TIP) program to the University of California, Los Angeles (UCLA) to develop a rapid, multiplexed diagnostic tool for serological testing of tick-borne diseases (TBDs). This 2-year project seeks to improve blood-based detection of TBDs, including Lyme disease, Babesia, Anaplasma, and relapsing fever, through an innovative point-of-care (POC) serological assay. The goal is...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,933 to L2 Diagnostics LLC to develop a novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor (SLPI). The goal is to demonstrate the feasibility of using SLPI to mitigate Lyme arthritis in a murine model, with the long-term objective of creating a SLPI-based therapeutic for advanced...
This Project Grant award for $300,000.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop rapid, point-of-care diagnostic tests for the early detection of leptospirosis, a potentially fatal zoonotic bacterial disease. The key objectives are to: Optimize and validate solid phase antigen-detection tests using leptospiral virulence-modifying proteins (VMP), lipoprotein LipL32, and...
The Virginia Commonwealth University was awarded a $746,009 Project Grant from the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases. The grant falls under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research examining the cyclic-di-GMP signaling pathway and its role in the enzootic cycle of Lyme disease from November 18, 2022 through October 31, 2027. Specifically, the grant will fund...
This $222,109 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a research project to investigate the impacts of the Borrelia burgdorferi GAC protein on infectivity and regulation of virulence protein expression in the Lyme disease spirochete. The key objectives of the study are to further characterize the functions of GAC, including its effects on mammalian and...
This $471,214 Project Grant award from the National Science Foundation's Biological Sciences (CFDA 47.074) program will fund research to improve the ability to predict Lyme disease risk. The Cary Institute of Ecosystem Studies, Inc., a non-profit research organization in Millbrook, NY, will execute the 5-year research project from April 2025 to March 2030. The research aims to better understand how factors like rodent populations, tree seed production, and climate conditions affect the life...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $797,183 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Big Eye Diagnostics Inc., a for-profit manufacturer of rapid diagnostic tests (RDTs). The funding will support the development and commercialization of a highly sensitive and specific RDT for the surveillance of lymphatic filariasis (LF) caused by Brugia species parasites. The new "Brugia Test Plus" (BT+) RDT...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Scribe Biosciences, Inc. a $300,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a high-throughput antibody discovery platform against cell membrane-bound proteins. Scribe Biosciences, a for-profit company specializing in microfluidics and biomedical engineering, will utilize its proprietary Microenvironment on Demand (MOD) technology to assemble over 100,000 single-cell...